Related Experiment Video
Updated: May 31, 2026
06:26
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
Published on: May 16, 2021
Fragment-based lead discovery: challenges and opportunities.
Chaohong Sun1, Andrew M Petros, Philip J Hajduk
1Pharmaceutical Discovery Division, Abbott Laboratories, Abbott Park, IL 60064-3500, USA.
Journal of Computer-Aided Molecular Design
|July 7, 2011
Summary
Fragment-based drug discovery has evolved significantly over 15 years. This article examines industry changes and their impact on future fragment-based lead discovery efforts.
Area of Science:
- Drug discovery and development
- Medicinal chemistry
- Pharmaceutical industry analysis
Background:
- Fragment-based lead discovery (FBLD) has seen substantial advancements.
- The pharmaceutical sector has experienced dramatic transformations.
- Ongoing industry evolution presents both challenges and opportunities for FBLD.
Purpose of the Study:
- To explore significant changes within the pharmaceutical industry.
- To assess the impact of these changes on fragment-based drug design initiatives.
- To identify future opportunities and challenges in FBLD.
Main Methods:
- Review of industry trends and their implications for FBLD.
- Analysis of the evolving landscape of pharmaceutical research and development.
- Discussion of strategic considerations for fragment-based approaches.
Main Results:
- FBLD has adapted to a dynamic pharmaceutical environment.
- Industry shifts create new avenues for fragment-based lead discovery.
- Strategic adaptation is crucial for leveraging FBLD opportunities.
Conclusions:
- The pharmaceutical industry's evolution necessitates adaptive strategies in FBLD.
- Future drug discovery efforts will benefit from understanding these industry dynamics.
- Fragment-based approaches remain a vital component of modern drug design.
